Biodesix to report Q2FY26 results on August 5, 2026
Biodesix will announce its Q2FY26 financial results on August 5, 2026, followed by a conference call at 4:30 p.m. ET. The company specializes in diagnostic solutions for lung disease, including Nodify Lung and IQLung tests.
*this image is generated using AI for illustrative purposes only.
Biodesix, Inc. will release its financial results for the second quarter ended June 30, 2026, after the close of trading on Wednesday, August 5, 2026. The diagnostic solutions company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss its financial performance and provide a general business update.
Conference Call Details
Biodesix management will conduct the earnings call to review the quarterly results. Analysts and investors can participate via webcast or phone. A replay will be available approximately two hours after the call concludes on the company’s investor website.
Registration and Access
| Event | Details |
|---|---|
| Webcast Registration | Available via company link |
| Analyst Q&A Participation | Separate registration required |
| Replay Availability | 2 hours post-call |
Participants are advised to join the webcast 15 minutes prior to the start time to ensure connectivity.
About Biodesix
Biodesix is a diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease. Its offerings include Biodesix Diagnostic Tests, such as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, as well as Biodesix Development Services, which support biopharmaceutical and life sciences institutions.
What market trends or factors might influence Biodesix's financial performance in Q2 2026?
How could advancements in lung disease diagnostics impact Biodesix's competitive position?
What strategic initiatives or partnerships might Biodesix announce during the earnings call?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
